DBVT DBV Technologies S.A. - American Depositary Shares
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Jul 16, 2026
$10,55
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$10,4752-Wochen-Tief
$26,1952-Wochen-Hoch
P/E (TTM)
-14.9
EPS (TTM)
$-0.71
Umsatz (TTM)
$5M
Ihre Abzeichen
52W-Spanne
$10–$26
Analystenbewertung
STRONG BUY
Kursziel
$39
P/E
-14.9
ROE
-142.7%
Nettogewinnmarge
-3507.2%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
DBVT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$10.55
P/E (TTM)
-14.9
EPS (TTM)
$-0.71
Umsatz (TTM)
$5M
ROE (TTM)
-142.7%
52W-Spanne
$10–$26
DBVT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 7. Juni 2024 | 1-for-2 | Umgekehrt |
Über DBV Technologies S.A. - American Depositary Shares Unternehmensübersicht von Wikipedia
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
History
DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter170
LandFR
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$6M2019-12-31 → 2025-12-31
EPS$-1.052021-12-31 → 2025-12-31
Freier Cashflow·2020-12-31 → 2023-12-31
Nettogewinnmarge-3507.2%2020-12-31 → 2023-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | DBVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -14.95-Jahres-Durchschnitt ≈-5.5 | ≈-5.5 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 11.6 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | DBVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -3543.8%5-Jahres-Durchschnitt ≈-1402.8% | ≈-1402.8% | · | · | |
| Vorgewinnmarge (TTM) | -3491.8%5-Jahres-Durchschnitt ≈-1389.5% | ≈-1389.5% | · | · | |
| Nettogewinnmarge (TTM) | -3507.2%5-Jahres-Durchschnitt ≈-1387.8% | ≈-1387.8% | · | · | |
| ROA (TTM) | -96.0%5-Jahres-Durchschnitt ≈-43.2% | ≈-43.2% | · | · | |
| ROE (TTM) | -142.7%5-Jahres-Durchschnitt ≈-63.0% | ≈-63.0% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | DBVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 3.75-Jahres-Durchschnitt ≈5.2 | ≈5.2 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | DBVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 35.8%5-Jahres-Durchschnitt ≈24.5% | ≈24.5% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 5.2%5-Jahres-Durchschnitt ≈2.3% | ≈2.3% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -13.0% | · | · | · | |
| Net Income YoY (Nettogewinn YoY) | -24.5% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | DBVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$33.2K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-29.7%
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | $-0.12 | $-0.10 | -18.8% | |
| 31. März 2026 | $-0.11 | $-0.08 | -36.1% | |
| 31. Dezember 2025 | $-0.23 | $-0.11 | -107.0% | |
| 30. September 2025 | $-0.24 | $-0.25 | 5.0% | |
| 30. Juni 2025 | $-0.31 | $-0.33 | 7.0% | |
| 30. Juni 2024 | $-0.34 | $-0.20 | -68.3% | |
| 31. März 2024 | $-0.28 | $-0.31 | 10.6% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M | $11M | $15M | |
| R&D Expense | $117M | $89M | $60M | $76M | $70M | $102M | $115M | |
| SG&A Expense | $33M | $29M | $30M | $24M | $31M | $35M | $49M | |
| Operating Expenses | $153M | $121M | $92M | $101M | $104M | $170M | $186M | |
| Operating Income | $-147M | $-117M | $-76M | $-97M | $-99M | $-159M | $-171M | |
| Pretax Income | $-146M | $-114M | $-73M | $-96M | $-98M | $-160M | $-171M | |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | $-381.0K | $-10.0K | $610.0K | |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M | $-160M | $-172M | |
| EPS (Basic) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| EPS (Diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| Shares (Basic) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| Shares (Diluted) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| EBITDA | · | · | $-76M | $-97M | $-99M | $-159M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194M | $32M | $141M | $209M | $77M | $196M | $193M | |
| Receivables | · | · | $0 | $0 | $0 | $2M | · | |
| Inventory | · | · | · | · | · | $0 | $2M | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $4M | $3M | $4M | |
| Other Current Assets | $19M | $12M | $18M | $14M | $37M | $9M | $9M | |
| Current Assets | $213M | $44M | $159M | $223M | $114M | $207M | $205M | |
| PP&E (Net) | $10M | $11M | $13M | $15M | $18M | $25M | $25M | |
| PP&E (Gross) | $33M | $29M | $32M | $30M | $32M | $41M | $36M | |
| Accum. Depreciation | $23M | $18M | $19M | $15M | $14M | $17M | $11M | |
| Intangibles | $0 | $40.0K | $58.0K | $10.0K | $22.0K | $41.0K | $48.0K | |
| Other Non-current Assets | $6M | $4M | $6M | $6M | $7M | $30M | $19M | |
| Total Assets | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Accounts Payable | $41M | · | · | · | · | · | · | |
| Current Liabilities | $58M | $31M | $37M | $30M | $31M | $53M | $54M | |
| Capital Leases | $5M | $6M | $5M | $1M | $7M | $10M | $22M | |
| Other Non-current Liabilities | · | $0 | $0 | $5M | $2M | $475.0K | $80.0K | |
| Total Liabilities | $65M | $38M | $43M | $52M | $47M | $67M | $79M | |
| Long-term Debt | · | · | · | · | $510.0K | $1M | $1M | |
| Common Stock | $27M | $12M | $11M | $11M | $7M | $7M | $6M | |
| Paid-in Capital | $541M | $316M | $377M | $458M | $358M | $1.15B | $1.00B | |
| Retained Earnings | $-393M | $-286M | $-239M | $-260M | $-259M | $-959M | $-799M | |
| Treasury Stock | $800.0K | $1M | $1M | $1M | $1M | $1M | $230.0K | |
| AOCI | $500.0K | $905.0K | $742.0K | $781.0K | $519.0K | $484.0K | $108.0K | |
| Stockholders' Equity | $169M | $27M | $140M | $194M | $99M | $205M | $193M | |
| Liabilities + Equity | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Shares Outstanding | · | 102,847,501 | · | · | 5,128,423 | 4,036,263 | 4,026,688 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $4M | · | · | · | · | |
| Stock-based Comp | $5M | $5M | $6M | $5M | $3M | $-1M | $17M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | · | · | · | $0 | $24M | · | |
| Operating Cash Flow | $-121M | $-104M | $-80M | $-56M | $-108M | $-166M | $-148M | |
| CapEx | $532.0K | $2M | $677.0K | $754.0K | $910.0K | $3M | $6M | |
| Investing Cash Flow | $-1M | $-757.0K | $-808.0K | $-100.0K | $-433.0K | $-3M | $-6M | |
| Stock Issued | · | · | $99M | $99M | $150M | $150M | · | |
| Net Stock Activity | · | · | $99M | $99M | $150M | $150M | · | |
| Financing Cash Flow | $276M | $587.0K | $7M | $194M | $274.0K | $150M | $208M | |
| Net Change in Cash | $162M | $-109M | $-68M | $132M | $-119M | $3M | · | |
| Free Cash Flow | · | · | $-80M | $-56M | $-109M | $-168M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| Net Margin | · | · | -462.4% | -1987.5% | -1713.5% | -1415.0% | · | |
| Pretax Margin | · | · | -462.4% | -1986.0% | -1720.2% | -1415.1% | · | |
| EBITDA Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| ROA | · | · | -33.9% | -49.0% | -46.7% | -58.7% | · | |
| ROE | · | · | -51.2% | -47.4% | -90.5% | -72.8% | · | |
| ROIC | · | · | -54.5% | -49.7% | -99.0% | -77.3% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.3 | 7.6 | 3.6 | 3.9 | · | |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 | 3.8 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.1 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 5.1 | 10.1 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | · | $19.36 | $50.91 | · | |
| Revenue / Share | · | · | $0.17 | $0.06 | · | · | · | |
| Cash Flow / Share | · | · | $-0.84 | $-0.72 | · | · | · | |
| Cash / Share | · | · | · | · | $15.07 | $48.65 | · | |
| EPS (TTM) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | · | · | |
| Revenue CAGR 3Y | 5.2% | -10.1% | 11.7% | · | · | · | · | |
| Revenue CAGR 5Y | -13.0% | · | · | · | · | · | · | |
| Net Income YoY | · | · | -24.5% | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $4M | $16M | $5M | $6M | $11M | · | |
| Net Income TTM | $-147M | $-114M | $73M | $96M | $-98M | $-160M | · | |
| Market Cap | · | · | · | · | $16M | $21M | · | |
| P/E | -18.3 | -2.6 | -2.5 | -2.5 | -1.8 | · | · | |
| P/S | · | · | · | · | 2.9 | 1.9 | · | |
| P/B | · | · | · | · | 0.2 | 0.1 | · | |
| P / Tangible Book | · | 11.6 | · | · | 0.2 | 0.1 | · | |
| P / Cash Flow | · | · | · | · | -0.2 | -0.1 | · | |
| P / FCF | · | · | · | · | -0.2 | -0.1 | · | |
| Earnings Yield | -5.5% | -37.9% | -39.9% | -40.5% | -55.6% | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $700.0K | $900.0K | $644.0K | $3M | $2M | $800.0K | $511.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | |
| R&D Expense | $31M | $33M | $33M | $29M | $34M | $22M | $19M | $24M | $25M | $21M | $14M | $18M | $16M | $15M | $19M | $12M | |
| SG&A Expense | $15M | $10M | $11M | $7M | $8M | $6M | $5M | $7M | $9M | $8M | $6M | $9M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $51M | $49M | $46M | $37M | $43M | $27M | $24M | $31M | $35M | $30M | $21M | $27M | $23M | $20M | $25M | $19M | |
| Operating Income | $-51M | $-48M | $-45M | $-34M | $-41M | $-27M | $-24M | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M | |
| Pretax Income | $-50M | $-47M | $-44M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| Income Tax | $200.0K | $200.0K | $374.0K | $0 | $100.0K | $0 | $7.0K | $0 | $0 | $48.0K | $0 | $13.0K | $0 | $0 | $0 | $87.0K | |
| Net Income | $-50M | $-48M | $-45M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| EPS (Basic) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| EPS (Diluted) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| Shares (Basic) | 433,535,486 | 428,302,850 | · | 136,811,952 | 134,476,503 | 102,617,429 | · | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| Shares (Diluted) | 433,535,486 | 428,302,850 | · | 136,811,952 | 134,476,503 | 102,617,429 | · | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| EBITDA | $-51M | $-48M | · | $-34M | $-41M | $-27M | · | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175M | $229M | $194M | $70M | $103M | $13M | $32M | $46M | $66M | $102M | $149M | $174M | $192M | $213M | $248M | $74M | |
| Prepaid Expense | $10M | $2M | $3M | $3M | $2M | $4M | $2M | $2M | $3M | $2M | $3M | $4M | $2M | $4M | $4M | $3M | |
| Other Current Assets | $27M | $18M | $19M | $19M | $18M | $16M | $12M | $22M | $24M | $18M | $20M | $22M | $18M | $13M | $12M | $16M | |
| Current Assets | $202M | $247M | $213M | $89M | $121M | $29M | $44M | $69M | $90M | $120M | $169M | $196M | $210M | $226M | $260M | $90M | |
| PP&E (Net) | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $13M | $13M | $13M | $13M | $14M | $15M | $14M | $16M | $17M | |
| PP&E (Gross) | $33M | · | $33M | · | · | · | $29M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $23M | · | $23M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | $100.0K | $22.0K | $21.0K | $26.0K | $29.0K | $40.0K | $43.0K | $46.0K | $52.0K | $61.0K | $68.0K | $10.0K | $11.0K | $14.0K | $18.0K | |
| Other Non-current Assets | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $5M | $5M | $7M | $6M | $6M | $6M | $5M | $6M | $7M | |
| Total Assets | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Accounts Payable | $39M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $54M | $52M | $58M | $49M | $49M | $40M | $31M | $31M | $27M | $26M | $31M | $33M | $33M | $28M | $30M | $26M | |
| Capital Leases | $7M | $5M | $5M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $94.0K | $187.0K | $680.0K | $1M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $3M | $4M | $4M | $979.0K | $2M | $1M | |
| Total Liabilities | $63M | $58M | $65M | $58M | $57M | $48M | $38M | $39M | $35M | $34M | $46M | $53M | $54M | $36M | $41M | $36M | |
| Common Stock | $34M | $34M | $27M | $15M | $15M | $12M | $12M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $7M | |
| Paid-in Capital | $408M | $626M | $541M | $392M | $392M | $317M | $316M | $316M | $315M | $379M | $376M | $376M | $460M | $457M | $456M | $359M | |
| Retained Earnings | $-270M | $-441M | $-393M | $-348M | $-315M | $-313M | $-286M | $-263M | $-233M | $-266M | $-228M | $-211M | $-280M | $-220M | $-203M | $-275M | |
| Treasury Stock | $800.0K | $1M | $834.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $953.0K | $1M | |
| AOCI | $500.0K | $400.0K | $497.0K | $502.0K | $861.0K | $1M | $905.0K | $709.0K | $750.0K | $683.0K | $761.0K | $687.0K | $698.0K | $783.0K | $743.0K | $543.0K | |
| Stockholders' Equity | $160M | $208M | $169M | $53M | $86M | $3M | $27M | $54M | $79M | $112M | $144M | $164M | $179M | $212M | $244M | $82M | |
| Liabilities + Equity | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Shares Outstanding | · | · | · | 136,975,159 | 136,973,697 | 102,858,868 | · | · | · | · | · | · | · | · | · | · |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $2M | $2M | $516.0K | $1M | $2M | $-453.0K | $2M | $2M | $2M | $1M | $2M | $2M | $975.0K | $1M | $1M | |
| Operating Cash Flow | $-53M | $-49M | $-35M | $-32M | $-34M | $-20M | $-12M | $-22M | $-35M | $-35M | $-20M | $-26M | $-21M | $-20M | $-10M | $-1M | |
| CapEx | $400.0K | $400.0K | $373.0K | $117.0K | $32.0K | $0 | $-125.0K | $396.0K | $732.0K | $1M | $50.0K | $164.0K | $111.0K | $373.0K | $238.0K | $131.0K | |
| Investing Cash Flow | $-600.0K | $-300.0K | $-715.0K | $-241.0K | $-38.0K | $-400.0K | $793.0K | $-109.0K | $691.0K | $-2M | $-322.0K | $-341.0K | $42.0K | $152.0K | $-229.0K | $11.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $100.0K | $89M | $159M | $130.0K | $117M | $0 | $675.0K | $7.0K | $-33.0K | $-62.0K | $-837.0K | $8M | $-14.0K | $-818.0K | $195M | $-129.0K | |
| Net Change in Cash | $-54M | $35M | $124M | $-33M | $90M | $-20M | $-14M | $-20M | $-35M | $-40M | $-25M | $-18M | $-17M | $-35M | $174M | $-3M | |
| Free Cash Flow | · | $-50M | · | · | · | $-20M | · | · | · | $-36M | · | · | $-21M | · | · | $-2M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| Net Margin | -7200.0% | -5288.9% | · | -1195.5% | -2858.4% | -3596.2% | · | -2839.7% | -2852.4% | -1943.5% | -705.6% | -1059.6% | -937.1% | -833.5% | -1506.8% | -656.2% | |
| Pretax Margin | -7171.4% | -5266.7% | · | -1195.5% | -2850.4% | -3596.2% | · | -2839.7% | -2852.4% | -1940.1% | -705.6% | -1059.0% | -937.1% | -833.5% | -1506.8% | -652.8% | |
| EBITDA Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| ROA | -27.5% | -30.0% | · | -32.6% | -32.5% | -27.6% | · | -21.5% | -20.0% | -14.4% | -7.6% | -9.7% | -11.7% | -8.2% | -9.5% | -9.9% | |
| ROE | -40.9% | -45.2% | · | -62.1% | -50.7% | -47.3% | · | -30.8% | -27.2% | -18.8% | -9.4% | -11.9% | -15.8% | -10.5% | -11.9% | -13.3% | |
| ROIC | -31.7% | -23.1% | · | -64.8% | -47.8% | -926.5% | · | -56.1% | -42.8% | -25.6% | -12.7% | -15.3% | -11.8% | -8.5% | -9.8% | -20.5% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.8 | · | 1.8 | 2.5 | 0.7 | · | 2.2 | 3.3 | 4.5 | 5.4 | 5.9 | 6.4 | 7.9 | 8.5 | 3.5 | |
| Quick Ratio | 3.2 | 4.4 | · | 1.4 | 2.1 | 0.3 | · | 1.5 | 2.4 | 3.8 | 4.7 | 5.2 | 5.9 | 7.5 | 8.1 | 2.8 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | $0.39 | $0.63 | $0.03 | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.00 | · | $0.02 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | · | |
| Cash Flow / Share | · | $-0.11 | · | · | · | $-0.19 | · | · | · | $-0.36 | · | · | $-0.22 | · | · | · | |
| Cash / Share | · | · | · | $0.51 | $0.75 | $0.13 | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.71 | $-0.90 | · | $-1.04 | $-1.12 | $-1.15 | · | · | · | · | · | · | · | $-1.08 | $-1.34 | $-1.55 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $6M | · | $6M | $4M | $4M | · | · | · | · | · | · | · | $9M | $8M | $5M | |
| Net Income TTM | $-176M | $-167M | · | $-125M | $-122M | $-114M | · | $43M | $57M | $66M | $92M | $91M | $92M | $-71M | $-77M | $-85M | |
| Market Cap | · | · | · | $1.37B | $1.25B | $701M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -23.1 | -23.2 | · | -9.6 | -8.2 | -5.9 | · | · | · | · | · | · | · | -3.3 | -3.8 | -2.1 | |
| P/S | · | · | · | 245.3 | 323.1 | 197.9 | · | · | · | · | · | · | · | · | · | · | |
| P/B | · | · | · | 25.9 | 14.6 | 244.2 | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 25.9 | 14.6 | 246.7 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | · | · | · | · | -35.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.3% | -4.3% | · | -10.4% | -12.2% | -16.9% | · | · | · | · | · | · | · | -30.5% | -26.3% | -48.7% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $6M | $4M | $16M | $5M | $6M |
| Betriebsgewinnmarge % | · | · | -486.0% | -1994.9% | -1727.6% |
| Nettoergebnis | $-147M | $-114M | $73M | $96M | $-98M |
| Verwässerte EPS | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | · | · | 4.3 | 7.6 | 3.6 |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | · | · | $-80M | $-56M | $-109M |
Institutionelle Eigentümer (13F) 78 Einreicher · $336.9M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
78
Gehaltener Wert
$336.9M
Neue Positionen
18
Geschlossene Positionen
11
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 18 (-12 vs. Vorquartal) | 11 (+1 vs. Vorquartal) | 16 (+3 vs. Vorquartal) | 24 (+12 vs. Vorquartal) | +575K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | $60.127.058 | 3.666.284 | 17,85% | Aktien |
| Siren, L.L.C. | $30.460.737 | 1.857.362 | 9,04% | Aktien |
| Vivo Capital, LLC | $30.254.031 | 1.844.758 | 8,98% | Aktien |
| PERCEPTIVE ADVISORS LLC | $27.114.940 | 1.653.350 | 8,05% | Aktien |
| BAKER BROS. ADVISORS LP | $23.967.370 | 1.461.425 | 7,11% | Aktien |
| Artisan Partners Limited Partnership | $22.514.756 | 1.372.851 | 6,68% | Aktien |
| UBS Group AG | $21.540.400 | 1.313.439 | 6,39% | Aktien |
| MORGAN STANLEY | $15.660.492 | 954.908 | 4,65% | Aktien |
| Logos Global Management LP | $15.006.000 | 915.000 | 4,45% | Aktien |
| Patient Square Capital LP | $14.915.374 | 909.474 | 4,43% | Aktien |
| Octagon Capital Advisors LP | $9.416.880 | 574.200 | 2,79% | Aktien |
| ADAR1 Capital Management, LLC | $8.664.038 | 528.295 | 2,57% | Aktien |
| Redmile Group, LLC | $6.731.216 | 410.440 | 2,00% | Aktien |
| AMERIPRISE FINANCIAL INC | $6.207.351 | 378.497 | 1,84% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $4.391.641 | 267.783 | 1,30% | Aktien |
| Elmind Capital, LP | $4.346.000 | 265.000 | 1,29% | Aktien |
| JANE STREET GROUP, LLC | $3.672.206 | 223.915 | 1,09% | Aktien |
| Ishara Investments LP | $3.025.800 | 184.500 | 0,90% | Aktien |
| Yiheng Capital Management, L.P. | $2.790.329 | 170.142 | 0,83% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.679.776 | 163.401 | 0,80% | Aktien |
| GREAT POINT PARTNERS LLC | $2.573.258 | 156.906 | 0,76% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.957.094 | 119.335 | 0,58% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $1.866.697 | 113.823 | 0,55% | Aktien |
| Ikarian Capital, LLC | $1.690.953 | 525.000 | 0,50% | Aktien |
| XTX Topco Ltd | $1.495.713 | 91.202 | 0,44% | Aktien |
| Russell Investments Group, Ltd. | $1.380.813 | 84.196 | 0,41% | Aktien |
| DIVERSIFY WEALTH MANAGEMENT, LLC | $1.246.716 | 89.692 | 0,37% | Aktien |
| Diversify Advisory Services, LLC | $1.246.716 | 89.692 | 0,37% | Aktien |
| Dorsey Wright & Associates | $1.199.086 | 73.115 | 0,36% | Aktien |
| Polymer Capital Management (HK) LTD | $1.057.800 | 64.500 | 0,31% | Aktien |
| DEUTSCHE BANK AG\ | $971.536 | 59.240 | 0,29% | Aktien |
| LPL Financial LLC | $881.516 | 53.751 | 0,26% | Aktien |
| AdvisorShares Investments LLC | $716.073 | 43.663 | 0,21% | Aktien |
| Cetera Investment Advisers | $578.215 | 35.257 | 0,17% | Aktien |
| Engineers Gate Manager LP | $532.000 | 32.439 | 0,16% | Aktien |
| Qube Research & Technologies Ltd | $472.402 | 28.805 | 0,14% | Aktien |
| STIFEL FINANCIAL CORP | $452.774 | 27.608 | 0,13% | Aktien |
| CITADEL ADVISORS LLC | $373.625 | 22.782 | 0,11% | Aktien |
| Burns Matteson Capital Management, LLC | $357.815 | 21.818 | 0,11% | Aktien |
| Atria Investments, Inc | $309.993 | 18.902 | 0,09% | Aktien |
| Persistent Asset Partners Ltd | $256.332 | 15.630 | 0,08% | Aktien |
| PERSONAL CFO SOLUTIONS, LLC | $212.216 | 12.940 | 0,06% | Aktien |
| Point72 Asset Management, L.P. | $199.227 | 12.148 | 0,06% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $190.732 | 11.630 | 0,06% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $189.813 | 11.574 | 0,06% | Aktien |
| SEI INVESTMENTS CO | $177.268 | 10.809 | 0,05% | Aktien |
| Integrated Wealth Concepts LLC | $170.051 | 10.369 | 0,05% | Aktien |
| China Universal Asset Management Co., Ltd. | $131.200 | 8.000 | 0,04% | Aktien |
| BARCLAYS PLC | $118.047 | 7.198 | 0,04% | Aktien |
| Optiver Holding B.V. | $105.862 | 6.455 | 0,03% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 Einreichungen | 14. Januar 2026 | 9,99% | Änderung | Passive Anlage | SEC |
| Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 Einreichungen | 7. Januar 2026 | 4,70% | Änderung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 11 Insider · 5 Führungskräfte · 4 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Daniel Tasse | CHIEF EXECUTIVE OFFICER | 21. November 2025 A | 17.094 | 0 | 0 | $0 |
| Virginie Boucinha | Chief Financial Officer | 21. November 2025 A | 70.000 | 0 | 0 | $0 |
| Sebastien Robitaille | Chief Financial Officer | 21. November 2022 A | 36.500 | 0 | 0 | $0 |
| Pharis Mohideen | Chief Medical Officer | 29. Juli 2026 S | 144.531 | 0 | 4 | $-27.054 |
| Kevin Michael Trapp | Chief Commercial Officer | 21. November 2025 A | 55.000 | 0 | 0 | $0 |
| Adora Ndu | Direktor | 6. Februar 2024 P | 1.825 | 0 | 0 | $0 |
| Timothy E Morris | Direktor | 25. August 2023 P | 12.000 | 0 | 0 | $0 |
| Daniel B Soland | Direktor | 1. August 2023 P | 20.000 | 0 | 0 | $0 |
| Viviane Monges | · | 10. Juni 2021 P | · | 0 | 0 | $0 |
| Madduri Ravin Rao | · | 10. Juni 2021 P | · | 0 | 0 | $0 |
| Michel De Rosen | · | 10. Juni 2021 P | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
DBVT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 8 Analysten
KAUF
Median-Ziel
$44.73
+324,0%
3 37,5%
Starker Kauf
3 37,5%
Kauf
1 12,5%
Halten
1 12,5%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
7 Analysten · 2026-09-28Mittelwert-Ziel $39.01 +269,8%
Jetzt
Aktueller Preis $10.55
Tief$5.78
Mittelwert$39.01
Hoch$54.68
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Jul 16, 2026